Edward Nash
Stock Analyst at Canaccord Genuity
(4.88)
# 328
Out of 4,376 analysts
375
Total ratings
50.9%
Success rate
26.2%
Average return
Main Sectors:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintained: Buy | $56 | $45.81 | +22.24% | 37 | Jun 2, 2026 | |
| KYMR Kymera Therapeutics | Maintained: Buy | $106 | $74.13 | +42.99% | 3 | Jun 1, 2026 | |
| CORT Corcept Therapeutics | Reiterated: Buy | $110 → $135 | $72.62 | +85.90% | 53 | May 28, 2026 | |
| APGE Apogee Therapeutics | Maintained: Buy | $130 | $86.92 | +49.56% | 14 | May 28, 2026 | |
| CNTB Connect Biopharma Holdings | Initiated Coverage: Buy | $6 | $2.17 | +176.50% | 1 | May 26, 2026 | |
| RANI Rani Therapeutics Holdings | Reiterated: Buy | $5 | $0.8295 | +502.77% | 16 | May 20, 2026 | |
| TSX: CRDL Cardiol Therapeutics Inc. | Reiterated: Buy | $11.12 | $1.57 | +608.50% | 24 | May 19, 2026 | |
| VERU Veru Inc. | Rated: Buy | $25 | $3.40 | +635.29% | 3 | May 14, 2026 | |
| PLRX Pliant Therapeutics | Maintained: Hold | $3 | $1.15 | +160.87% | 15 | May 12, 2026 | |
| SGMT Sagimet Biosciences | Maintained: Buy | $49 | $6.76 | +624.85% | 11 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $62 | $28.62 | +116.63% | 11 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $101 | $37.58 | +168.76% | 2 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $587 → $578 | $486.98 | +18.69% | 40 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $107 | $28.45 | +276.10% | 7 | May 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $62 → $64 | $48.42 | +32.18% | 3 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 | $4.03 | +396.28% | 14 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $4.25 | n/a | 8 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2 | $3.71 | n/a | 6 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $15 | $0.696 | n/a | 15 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $12 → $1 | $0.00001 | n/a | 2 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $4.29 | n/a | 2 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 → $11 | $31.27 | n/a | 7 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 | $1.84 | n/a | 1 | Jun 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 → $39 | $5.73 | n/a | 9 | May 20, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $176 | $15.75 | n/a | 15 | Feb 27, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $48 → $64 | $26.45 | n/a | 2 | Feb 26, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $126 → $117 | $56.77 | n/a | 14 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $54 → $71 | $21.91 | n/a | 11 | Jan 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $156 | $50.37 | n/a | 1 | Sep 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $132 | $891.32 | n/a | 1 | Sep 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $22 → $4 | $14.77 | n/a | 3 | Jun 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $26 | $6.20 | n/a | 1 | Jun 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $26 → $23 | $5.47 | n/a | 2 | May 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $0.0001 | n/a | 1 | Sep 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 → $2 | $0.001 | n/a | 2 | May 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $6 | $3.17 | n/a | 8 | May 5, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $9 | $12.77 | n/a | 3 | Mar 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $14 → $11 | $3.31 | n/a | 3 | Sep 4, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $0.215 | n/a | 1 | Jun 17, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $10.67 | n/a | 2 | May 3, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $21.56 | n/a | 1 | Jan 28, 2013 |
Travere Therapeutics
Jun 2, 2026
Maintained: Buy
Price Target: $56
Current: $45.81
Upside: +22.24%
Kymera Therapeutics
Jun 1, 2026
Maintained: Buy
Price Target: $106
Current: $74.13
Upside: +42.99%
Corcept Therapeutics
May 28, 2026
Reiterated: Buy
Price Target: $110 → $135
Current: $72.62
Upside: +85.90%
Apogee Therapeutics
May 28, 2026
Maintained: Buy
Price Target: $130
Current: $86.92
Upside: +49.56%
Connect Biopharma Holdings
May 26, 2026
Initiated Coverage: Buy
Price Target: $6
Current: $2.17
Upside: +176.50%
Rani Therapeutics Holdings
May 20, 2026
Reiterated: Buy
Price Target: $5
Current: $0.8295
Upside: +502.77%
Cardiol Therapeutics Inc.
May 19, 2026
Reiterated: Buy
Price Target: $11.12
Current: $1.57
Upside: +608.50%
Veru Inc.
May 14, 2026
Rated: Buy
Price Target: $25
Current: $3.40
Upside: +635.29%
Pliant Therapeutics
May 12, 2026
Maintained: Hold
Price Target: $3
Current: $1.15
Upside: +160.87%
Sagimet Biosciences
May 12, 2026
Maintained: Buy
Price Target: $49
Current: $6.76
Upside: +624.85%
May 8, 2026
Maintained: Buy
Price Target: $62
Current: $28.62
Upside: +116.63%
May 8, 2026
Reiterated: Buy
Price Target: $101
Current: $37.58
Upside: +168.76%
May 7, 2026
Maintained: Buy
Price Target: $587 → $578
Current: $486.98
Upside: +18.69%
May 4, 2026
Reiterated: Buy
Price Target: $107
Current: $28.45
Upside: +276.10%
Apr 29, 2026
Rated: Buy
Price Target: $62 → $64
Current: $48.42
Upside: +32.18%
Apr 2, 2026
Maintained: Buy
Price Target: $20
Current: $4.03
Upside: +396.28%
Oct 2, 2024
Maintained: Buy
Price Target: $9
Current: $4.25
Upside: n/a
May 17, 2023
Maintained: Hold
Price Target: $2
Current: $3.71
Upside: n/a
Aug 8, 2022
Downgraded: Hold
Price Target: $5 → $15
Current: $0.696
Upside: n/a
Jul 29, 2022
Downgraded: Hold
Price Target: $12 → $1
Current: $0.00001
Upside: n/a
May 18, 2021
Maintained: Buy
Price Target: $25
Current: $4.29
Upside: n/a
Aug 9, 2019
Maintained: Buy
Price Target: $9 → $11
Current: $31.27
Upside: n/a
Jun 5, 2019
Downgraded: Hold
Price Target: $5
Current: $1.84
Upside: n/a
May 20, 2019
Maintained: Buy
Price Target: $60 → $39
Current: $5.73
Upside: n/a
Feb 27, 2019
Reiterated: Buy
Price Target: $176
Current: $15.75
Upside: n/a
Feb 26, 2019
Maintained: Buy
Price Target: $48 → $64
Current: $26.45
Upside: n/a
Feb 25, 2019
Maintained: Buy
Price Target: $126 → $117
Current: $56.77
Upside: n/a
Jan 23, 2019
Maintained: Buy
Price Target: $54 → $71
Current: $21.91
Upside: n/a
Sep 24, 2018
Maintained: Buy
Price Target: $156
Current: $50.37
Upside: n/a
Sep 17, 2018
Maintained: Buy
Price Target: $132
Current: $891.32
Upside: n/a
Jun 27, 2018
Downgraded: Hold
Price Target: $22 → $4
Current: $14.77
Upside: n/a
Jun 25, 2018
Initiated Coverage: Buy
Price Target: $26
Current: $6.20
Upside: n/a
May 16, 2018
Maintained: Buy
Price Target: $26 → $23
Current: $5.47
Upside: n/a
Sep 18, 2017
Maintained: Buy
Price Target: $24
Current: $0.0001
Upside: n/a
May 16, 2017
Reiterated: Hold
Price Target: $1 → $2
Current: $0.001
Upside: n/a
May 5, 2017
Reiterated: Hold
Price Target: $3 → $6
Current: $3.17
Upside: n/a
Mar 7, 2017
Reiterated: Hold
Price Target: $9
Current: $12.77
Upside: n/a
Sep 4, 2014
Downgraded: Hold
Price Target: $14 → $11
Current: $3.31
Upside: n/a
Jun 17, 2013
Initiated Coverage: Buy
Price Target: n/a
Current: $0.215
Upside: n/a
May 3, 2013
Downgraded: Sell
Price Target: n/a
Current: $10.67
Upside: n/a
Jan 28, 2013
Initiated Coverage: Buy
Price Target: n/a
Current: $21.56
Upside: n/a